<DOC>
<DOCNO>
EP-0002570
</DOCNO>
<TEXT>
<DATE>
19790627
</DATE>
<IPC-CLASSIFICATIONS>
C07D-491/06 C07D-209/90 A61K-31/403 A61P-25/00 C07D-491/00 A61K-31/40 <main>C07D-209/90</main> C07D-209/00 A61P-43/00 
</IPC-CLASSIFICATIONS>
<TITLE>
tetrahydrobenz(cd)indoles, their production and pharmaceutical formulations containing them.
</TITLE>
<APPLICANT>
lilly co eli us  <sep>eli lilly and company<sep>eli lilly and company307, east mccarty streetindianapolis indiana 46285us<sep>eli lilly and company  <sep>
</APPLICANT>
<INVENTOR>
bach nicholas james<sep>kornfeld edmund carl<sep>bach, nicholas james<sep>kornfeld, edmund carl<sep>bach, nicholas james4269 burkhart east driveindianapolis indiana 46227us<sep>kornfeld, edmund carl5159 e. 76 courtindianapolis indianaus<sep>bach, nicholas james<sep>kornfeld, edmund carl<sep>bach, nicholas james4269 burkhart east driveindianapolis indiana 46227us<sep>kornfeld, edmund carl5159 e. 76 courtindianapolis indianaus<sep>
</INVENTOR>
<ABSTRACT>
a compound of the formula    and its pharmaceutically acceptable salts is prepared by  hydrolysis of 1-benzoyl-4-(di-n-propyl) amino-1, 2, 2a, 3, 4, 5-hexahydrobenz(cd)indole  and the subsequent oxidation of  4-(di-n-propyl)amino-1, 2, 2a, 3, 4, 5-hexahydrobenz(cd)indole.  the compounds are useful as prolactin inhibitors and in  the treatment of parkinsonism.  
</ABSTRACT>
</TEXT>
</DOC>
